Product Images Fluzone High-dose Quadrivalent Northern Hemisphere

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 4 images provide visual information about the product associated with Fluzone High-dose Quadrivalent Northern Hemisphere NDC 49281-123 by Sanofi Pasteur Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

PRINCIPAL DISPLAY PANEL - 0.7 mL Syringe Label - fluzone 01

PRINCIPAL DISPLAY PANEL - 0.7 mL Syringe Label - fluzone 01

PRINCIPAL DISPLAY PANEL - 0.7 mL Syringe Package - fluzone 02

PRINCIPAL DISPLAY PANEL - 0.7 mL Syringe Package - fluzone 02

This is a description of the Fluzone® High-Dose Beony Quadrivalent Influenza Vaccine. The vaccine is intended for individuals who are 65 years of age and older and is administered via injection. The specific lot number and expiration date are not provided in the given text. The vaccine is manufactured by Sanofi Pasteur Inc. and uses the 2022-2023 formula.*

fluzone 03

fluzone 03

This text contains a mixture of readable characters and non-readable characters that appear to be the result of errors during the process. The readable text includes a reference to an intramuscular injection for an influenza vaccine called Fluzone High-Dose Quadrivalent, manufactured by Sanofi Pasteur Inc. The vaccine comes in pre-filled syringes and is indicated for individuals over the age of 65. There is also a reference to a formula and NDC number for the 2022-2023 flu season. The bottom area contains a space reserved for Lot, Expiry, SN & GTIN.*

fluzone 04

fluzone 04

This is a description of the Fluzone High-Dose Quadrivalent influenza vaccine. It is for intramuscular injection only and should not be frozen. The vaccine contains influenza viruses propagated in embryoated chickens and inactivated with formaldehyde. It is standardized according to USPHS requirements and formulated to contain 3.3-4.8 micrograms (μg) hemagglutinin (HA) per 0.7 mL dose, recommended for the 2022-2023 influenza season. The vaccine contains four prototype strains, including two influenza A strains and two influenza B strains. The vaccine is preservative-free and does not contain natural rubber latex. The vaccine is packaged in single-dose prefilled syringes. More information can be found in the full prescribing information.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.